Project description:The research of a specific oral mucosa epithelial marker was performed by microarray analysis of holoclones derived from cornea, conjunctiva and oral mucosa tissues. The results identified SOX2 and PAX6 as positive and negative markers to assess the presence (or absence) of oral epithelium onto the ocular surface.
Project description:Pathological neovascularization and vascular leakage are central drivers of many sight- threatening diseases. While strategies targeting vascular endothelial growth factor (VEGF) have transformed clinical outcomes, a substantial proportion of patients do not benefit from the treatment, partially attributed to compensatory activation of alternative angiogenic pathways. Two independent vitreous proteomics studies in patients with proliferative diabetic retinopathy (PDR) revealed a significant reduction in the level of Frizzled-related Protein (FRZB), a finding mirrored in preclinical models of ocular angiogenesis. Loss of Frzb in mice exacerbated ocular angiogenesis, while therapeutic delivery of Fc-FRZB recombination protein or its functional domain netrin-related motif (NTR) potently suppressed and reversed ocular angiogenesis across various preclinical models. Notably, Fc-NTR synergized with Aflibercept, suggesting its potential as a combination therapy. Mechanistically, FRZB doesn’t modulate Wnt signalling in retinal microvascular endothelial cells. Instead, it binds directly to Caveolin-1 (CAV1), inhibits its phosphorylation, promotes surface retention of the TGFβ type I receptor ALK5, and ultimately leads to cytoplasmic accumulation of phosphorylated Smad2/3. Intriguingly, retinal endothelial cells expressing a phosphomimetic CAV1 mutant (Y42D) at a previously uncharacterized site, Tyr42, were resistant to FRZB’s anti-angiogenic effects, establishing a novel CAV1–TGFβ signalling axis as the molecular basis of FRZB’s action. Collectively, these findings define FRZB as a novel suppressor of ocular angiogenesis, uncover a previously unknown mechanism of TGFβ regulation, and establish Fc-NTR as a promising therapeutic candidate for treating ocular angiogenic diseases.
Project description:Pathological neovascularization and vascular leakage are central drivers of many sight- threatening diseases. While strategies targeting vascular endothelial growth factor (VEGF) have transformed clinical outcomes, a substantial proportion of patients do not benefit from the treatment, partially attributed to compensatory activation of alternative angiogenic pathways. Two independent vitreous proteomics studies in patients with proliferative diabetic retinopathy (PDR) revealed a significant reduction in the level of Frizzled-related Protein (FRZB), a finding mirrored in preclinical models of ocular angiogenesis. Loss of Frzb in mice exacerbated ocular angiogenesis, while therapeutic delivery of Fc-FRZB recombination protein or its functional domain netrin-related motif (NTR) potently suppressed and reversed ocular angiogenesis across various preclinical models. Notably, Fc-NTR synergized with Aflibercept, suggesting its potential as a combination therapy. Mechanistically, FRZB doesn’t modulate Wnt signalling in retinal microvascular endothelial cells. Instead, it binds directly to Caveolin-1 (CAV1), inhibits its phosphorylation, promotes surface retention of the TGFβ type I receptor ALK5, and ultimately leads to cytoplasmic accumulation of phosphorylated Smad2/3. Intriguingly, retinal endothelial cells expressing a phosphomimetic CAV1 mutant (Y42D) at a previously uncharacterized site, Tyr42, were resistant to FRZB’s anti-angiogenic effects, establishing a novel CAV1–TGFβ signalling axis as the molecular basis of FRZB’s action. Collectively, these findings define FRZB as a novel suppressor of ocular angiogenesis, uncover a previously unknown mechanism of TGFβ regulation, and establish Fc-NTR as a promising therapeutic candidate for treating ocular angiogenic diseases.
Project description:To investigate the function of histone lactylation in ocular melanoma, we analyzed histone lactylation enrichment level in ocular melanoma by CUT&Tag.
Project description:To investigate the function of histone lactylation in ocular melanoma, we analyzed histone lactylation enrichment level in ocular melanoma by CHIP-seq.
Project description:The homeobox-containing transcription factor PAX6 is a key regulator of eye development. Pathogenic heterozygous PAX6 variants lead to variable ocular phenotypes. Missense variants are often associated with milder ocular conditions, although variants in the DNA-binding paired domain which alter target binding lead to severe ocular phenotypes including bilateral microphthalmia, similar to SOX2 anophthalmia syndrome. However, the variant-specific pathway disruption resulting in phenotypic heterogeneity is not well understood.
2025-05-22 | GSE288050 | GEO
Project description:Sequencing of microglia treated with Fc or STREM2-Fc
| PRJNA986962 | ENA
Project description:Sequencing of microglia treated with Fc or STREM2-Fc
Project description:We investigated the RNAPII and γH2AX occupancy genome wide by ChIP-Seq in MLL2 F/F and FC/FC80 MEF cells. We found that a week after MLL2 excision (FC/FC cells), a group of genes present higher levels of γH2AX and RNAPII near the TSS, as compared to the control (F/F cells). H3K4Me1, H3K4M2 and H3K4Me3 levels near the TSS were also studied.